Le Lézard
Classified in: Health
Subject: FDA

Inovise Receives Breakthrough Device Designation for Novel Non-Invasive System to Remotely Monitor Risk of Decompensation in Heart Failure Patients


PORTLAND, Ore., Feb. 23, 2021 /PRNewswire/ -- Inovise Medical today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its AUDICOR® heart failure management system. The system uses clinically tested algorithms to detect the risk of decompensation at home in patients who have been previously hospitalized for heart failure.

Michael Mirro, MD, Director of the Parkview Mirro Center for Research and Innovation, and Clinical Professor of Medicine at Indiana University, commented, "This technology promises to enhance the management of heart failure patients and keep them out of the hospital. Early detection of potential problems outside of the hospital can allow clinicians to modify the patients' therapeutic regimens and maintain their stable condition."

The AUDICOR heart failure management system is non-invasive and assesses the mechanical efficiency, as well as the electrical activity, of the heart. Signals are acquired through a hand-held device that connects to a smart phone for analysis in the cloud. This analysis of the signals produces proprietary cardiac acoustic biomarkers, which have been shown to provide actionable data to optimize therapy and improve patient outcomes. Physicians receive notifications based on biomarker trends and values, allowing them to modify patient therapy (e.g., change drug dosage) before there is a significant deterioration of heart failure status requiring hospitalization.

"The most significant advantages of this new technology are enhanced ease of use, eliminated risks of surgical complications, and significantly reduced costs compared to permanently implanted physiologic sensors currently on the market," said Peter Bauer, Ph.D., CEO of Inovise Medical

About the Breakthrough Devices Program

The Breakthrough Devices Program offers manufacturers an opportunity to interact with the FDA's experts through several different program options to efficiently address topics as they arise during the premarket review phase. Manufacturers can expect prioritized review of their submission. Innovative products that the FDA approves as part of the Breakthrough Devices Program will also benefit from the recently approved Medicare Coverage of Innovative Technology (MCIT) rule which creates a new, accelerated Medicare coverage pathway.

About Inovise Medical, Inc.

Inovise Medical has been applying artificial intelligence and machine learning techniques, as well as traditional algorithm development, to the problem of heart failure for 15 years. To learn more about Inovise Medical, visit https://inovise.com/.

CONTACT
Gregg Harris, BS, MBA
Director, Regulatory Affairs & QA
Inovise Medical, Inc.
[email protected]
(503) 431-3820

Related Images

audicor-heart-failure-management.png
AUDICOR heart failure management system

Related Links

LinkedIn

SOURCE Inovise Medical, Inc.


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: